View Post

Rare Patient Voice: Paid Opportunity for Acute Myeloid Leukemia (AML) Patients in the US

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 15 min Voice Response Compensation $25 * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why Sign up with Rare Patient Voice? …

View Post

Rare Patient Voice: Acute Myeloid Leukemia Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 90 min Web-Assisted Phone Interview Compensation $200 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Rare Patient Voice: Acute Myeloid Leukemia Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

AbbVie, Roche leukemia drug successful in Phase III confirmatory study

In Clinical Studies News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The companies said Venclexta extended overall survival in untreated acute myeloid leukemia patients when combined with Bristol-Myers Squibb’s VidazaVenclexta. A prior Phase III confirmatory trial, combining the drug with low-dose cytarabine, failed. A cancer drug made by Chicago-based AbbVie and Swiss drugmaker Roche was successful in a Phase III confirmatory trial in an aggressive form …

View Post

BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor

In Clinical Studies News by Barbara Jacoby

Source: BioTheryX, Inc. Study is evaluating the safety/tolerability of BTX-A51 in patients with relapsed/refractory acute myeloid leukemia (AML), as well as high risk myelodysplastic syndrome patients. BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase inhibition and targeted protein degradation, today announced the initiation of patient dosing in its first clinical program. The Phase …

View Post

Celgene’s CC-486 positioned to become standard maintenance therapy in acute myeloid leukemia

In Clinical Studies News by Barbara Jacoby

Source: Global Data From: prnewswire.com Celgene plans to pursue a new drug application (NDA) in Q1 2020 for its formulation of oral azacitidine (CC-486) after data from the Phase III QUAZAR AML-001 trial showed that maintenance therapy can prolong the overall survival (OS) of acure myeloid leukemia (AML) patients compared with placebo. As such, CC-486 is set to address a …

View Post

Savvy Cooperative Opportunity: Share Your Expertise as an Acute Myeloid Leukemia (AML) patient

In In The News by Barbara Jacoby

Click on the link below to see whether you qualify: Interview: Share your thoughts on living with Acute Myeloid Leukemia (AML) (Anywhere) – $125 Description: We are working on a new project and we are hoping to speak with Acute Myeloid Leukemia (AML) patients and hear about your experience living with the condition and thoughts about your current treatment regimen. …

View Post

Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory AML or Higher Risk MDS

In Clinical Studies News by Barbara Jacoby

From: prnewswire.com – Milestone represents the first patient dosed with Precigen’s transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the …

View Post

BioTheryX Announces FDA approval of IND Application to Initiate Phase I Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia

In Clinical Studies News by Barbara Jacoby

Expects Enrollment of Phase I Trial to Begin in the Third Quarter of 2019 BioTheryX, Inc. (“BioTheryX”), a biotechnology company creating new classes of drugs based on multi-kinase inhibition and targeted protein degradation, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared BioTheryX’s investigational new drug application (“IND”) for BTX-A51, an oral multi-kinase inhibitor, for the treatment …

View Post

EARLY CANCER DEATHS LINKED TO BEING SINGLE, LIVING IN A POOR NEIGHBORHOOD

In In The News by Barbara Jacoby

Patients in California hospitals were more likely to die within 60 days of being diagnosed with acute myeloid leukemia – a cancer of the blood and bone marrow – if they were unmarried, lived in a less-affluent neighborhood or lacked health insurance. The UC Davis study also found that patients treated at a National Cancer Institute (NCI)-designated cancer center were …